Compare Altria Group Inc (MO) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Tilray Brands Inc — how do they compare? Altria Group Inc trades at $68.02 (market cap $113.83B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Altria Group Inc is far larger — about 192.4× Tilray Brands Inc's market cap, and Altria Group Inc pays a 6.51% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| MO | TLRY | |
|---|---|---|
Market Cap | $113.83B | $591.60M |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $21.00 |
52-Week Low | $54.72 | $3.88 |
Enterprise Value | $136.04B | $758.73M |
Dividend Yield | 6.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $68.18, down 1.02% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock offers a high dividend yield of 6.45% following its 61st annual increase. Recent earnings show mixed quarterly results, with Q1 2026 beating expectations but Q2 2026 missing. Revenue remains stable around $20.1 billion (2025), with strong profitability margins, though net income declined to $6.95 billion in 2025 from $11.3 billion in 2024. Analyst consensus is bullish with a $68.50 price target.
MO presents a value opportunity with a low P/E of 14.35 and robust cash flows supporting dividends, but faces risks from regulatory lawsuits, declining cigarette volumes, and high debt levels. The stock's appeal hinges on dividend sustainability amid secular challenges in the tobacco industry.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
